Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001
NCT05511350 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2022-10-18
Summary
This EAP was designed to provide TJ210001 to the remaining subjects with relapsed or refractory solid tumors who were enrolled on the parent study, TJ210001STM101 (NCT04678921), and plan to continue with treatment.
Conditions
- Solid Tumor Metastatic Cancer Advanced Cancer
Interventions
- DRUG
-
TJ210001
Sponsors & Collaborators
-
I-Mab Biopharma US Limited
lead INDUSTRY
Principal Investigators
-
Laura Feller, NP · Horizon Oncology Center
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors
NCT05494762 ·Status: TERMINATED ·Phase: PHASE1
-
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
NCT03114319 ·Status: TERMINATED ·Phase: PHASE1
-
Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors
NCT05653661 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
NCT07213830 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors
NCT05631327 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
NCT05473156 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
NCT04780217 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
NCT00121290 ·Status: COMPLETED ·Phase: PHASE1
-
A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.
NCT00493155 ·Status: COMPLETED ·Phase: PHASE1
-
Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
NCT03835949 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors
NCT04809012 ·Status: WITHDRAWN ·Phase: PHASE2
-
Safety Study of Sterile Compound C31510 for Injection to Subjects With Solid Tumors
NCT01251562 ·Status: COMPLETED ·Phase: PHASE1
-
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
NCT03595059 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
NCT00811993 ·Status: TERMINATED ·Phase: PHASE1
-
A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.
NCT00676910 ·Status: COMPLETED ·Phase: PHASE1
-
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
NCT01332721 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
NCT04419532 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
NCT05075564 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors
NCT05108623 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
NCT07196644 ·Status: RECRUITING ·Phase: PHASE2
-
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
NCT01618136 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors
NCT00001209 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
NCT02715531 ·Status: COMPLETED ·Phase: PHASE1
-
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
NCT04649385 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Clinical Trial of TB511 in Advanced Solid Tumors
NCT06400160 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2